These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
549 related items for PubMed ID: 31016475
1. Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist. Chang KL, Wong LR, Pee HN, Yang S, Ho PC. Mol Neurobiol; 2019 Nov; 56(11):7267-7283. PubMed ID: 31016475 [Abstract] [Full Text] [Related]
2. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease. González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL. Biochim Biophys Acta; 2014 Dec; 1842(12 Pt A):2395-402. PubMed ID: 25281826 [Abstract] [Full Text] [Related]
5. Albiflorin ameliorates memory deficits in APP/PS1 transgenic mice via ameliorating mitochondrial dysfunction. Xu YJ, Mei Y, Shi XQ, Zhang YF, Wang XY, Guan L, Wang Q, Pan HF. Brain Res; 2019 Sep 15; 1719():113-123. PubMed ID: 31150651 [Abstract] [Full Text] [Related]
9. Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice. Ettcheto M, Petrov D, Pedrós I, Alva N, Carbonell T, Beas-Zarate C, Pallas M, Auladell C, Folch J, Camins A. J Alzheimers Dis; 2016 Jul 14; 54(1):233-51. PubMed ID: 27567882 [Abstract] [Full Text] [Related]
10. The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer's disease. Zheng H, Zhou Q, Du Y, Li C, Xu P, Lin L, Xiao J, Gao H. Biochim Biophys Acta Mol Basis Dis; 2018 Jan 14; 1864(1):263-273. PubMed ID: 29107091 [Abstract] [Full Text] [Related]
15. Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease. Bilousova T, Taylor K, Emirzian A, Gylys R, Frautschy SA, Cole GM, Teng E. Neurobiol Dis; 2015 Feb 14; 74():32-40. PubMed ID: 25449907 [Abstract] [Full Text] [Related]
17. PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. Silva-Abreu M, Calpena AC, Andrés-Benito P, Aso E, Romero IA, Roig-Carles D, Gromnicova R, Espina M, Ferrer I, García ML, Male D. Int J Nanomedicine; 2018 Feb 14; 13():5577-5590. PubMed ID: 30271148 [Abstract] [Full Text] [Related]
18. CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice. Yin K, Jin J, Zhu X, Yu L, Wang S, Qian L, Han L, Xu Y. Neurol Res; 2017 Oct 14; 39(10):885-894. PubMed ID: 28743230 [Abstract] [Full Text] [Related]
19. Upregulation of PGC-1α expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP. Robinson A, Grösgen S, Mett J, Zimmer VC, Haupenthal VJ, Hundsdörfer B, Stahlmann CP, Slobodskoy Y, Müller UC, Hartmann T, Stein R, Grimm MO. Aging Cell; 2014 Apr 14; 13(2):263-72. PubMed ID: 24304563 [Abstract] [Full Text] [Related]
20. β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Cheng Y, Dong Z, Liu S. Pharmacology; 2014 Apr 14; 94(1-2):1-12. PubMed ID: 25171128 [Abstract] [Full Text] [Related] Page: [Next] [New Search]